<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529449</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-6001</org_study_id>
    <nct_id>NCT02529449</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Phase 2, Clinical Pharmacological Study of ASP1941 in Japanese Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess pharmacodynamics, pharmacokinetics, and safety of&#xD;
      ASP1941 in patients with type 1 diabetes mellitus when administered once daily (q.d.) for 2&#xD;
      weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">March 19, 2016</completion_date>
  <primary_completion_date type="Actual">March 19, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily profile of plasma glucose levels</measure>
    <time_frame>up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) 0-24hr (AUC0-24h) of plasma glucose levels</measure>
    <time_frame>at Day -1, Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-3h of plasma glucose levels</measure>
    <time_frame>at Day -1, Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-4h of plasma glucose levels</measure>
    <time_frame>up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-10h of plasma glucose levels</measure>
    <time_frame>up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting plasma glucose levels</measure>
    <time_frame>up to Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycoalbumin</measure>
    <time_frame>up to Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary glucose excretion</measure>
    <time_frame>up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary glucose excretion rate</measure>
    <time_frame>up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine volume</measure>
    <time_frame>up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary glucose concentration</measure>
    <time_frame>up to Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>up to Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal glucose clearance</measure>
    <time_frame>up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of unchanged ASP1941</measure>
    <time_frame>up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary concentration of unchanged ASP1941</measure>
    <time_frame>up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter of ASP1941 in plasma: AUC from time 0 extrapolated to infinity (AUCinf)</measure>
    <time_frame>at Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1941 in plasma: AUC from the time of dosing to the last measurable concentration (AUClast)</measure>
    <time_frame>at Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1941 in plasma: AUC from the time of dosing to 24 hr (AUC0-24h)</measure>
    <time_frame>at Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1941 in plasma: Oral Clearance (CL/F)</measure>
    <time_frame>at Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1941 in plasma: Maximum concentration (Cmax)</measure>
    <time_frame>at Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1941 in plasma: Terminal Elimination Half-life (t1/2)</measure>
    <time_frame>at Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1941 in plasma: Time of the Maximum Concentration (tmax)</measure>
    <time_frame>at Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1941 in urine: Amount excreted in urine between time (Ae)</measure>
    <time_frame>at Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1941 in urine: % of the dose of excreted in urine (Ae%)</measure>
    <time_frame>at Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1941 in plasma and urine: Renal Clearance (CLr)</measure>
    <time_frame>at Day 1 and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by vital signs</measure>
    <time_frame>up to Day 21</time_frame>
    <description>Supine blood pressure and supine pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by 12-lead electrocardiogram</measure>
    <time_frame>up to Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by laboratory tests</measure>
    <time_frame>up to Day 21</time_frame>
    <description>Hematology, biochemistry and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by self-monitored blood glucose levels</measure>
    <time_frame>up to Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Adverse events</measure>
    <time_frame>up to Day 21</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1941 Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1941 Middle dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1941 High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>Oral</description>
    <arm_group_label>ASP1941 High dose group</arm_group_label>
    <arm_group_label>ASP1941 Low dose group</arm_group_label>
    <arm_group_label>ASP1941 Middle dose group</arm_group_label>
    <other_name>Suglat</other_name>
    <other_name>Ipragliflozin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        At the time of obtaining informed consent:&#xD;
&#xD;
          -  Subject is diagnosed with type 1 diabetes mellitus and has been treated with insulin&#xD;
             therapy for at least 52 weeks (364 days).&#xD;
&#xD;
          -  Subject is able to be admitted to the site as scheduled.&#xD;
&#xD;
          -  Subject is able to record in Patient's diary from the first study drug dose in&#xD;
             observation period until the day before the end of post observation.&#xD;
&#xD;
        At screening period:&#xD;
&#xD;
          -  Subject has an HbA1c (NGSP) value of between 7.5% and 10.0%. If subject has an HbA1c&#xD;
             value of between 7.3% and 10.2% (out of the reference range), HbA1c may be re-measured&#xD;
             only once within the allowance range in screening period. Re-measured HbA1c (NGSP)&#xD;
             value will be adopted for the determination.&#xD;
&#xD;
          -  Subject has been receiving insulin therapy at daily doses (instructed by a doctor)&#xD;
             within a ±20% range for at least 12weeks (83days) prior to the start of screening.&#xD;
&#xD;
          -  Subject has a fasting serum C-peptide level ≤0.5 ng/mL at screening.&#xD;
&#xD;
          -  Subject receives treatments for complications (except for transient diseases such as a&#xD;
             cold) that, in the investigator's or sub-investigator's opinion, need not to be&#xD;
             changed during the period from the start of screening to the end of the treatment&#xD;
             period.&#xD;
&#xD;
          -  Subject has body mass index (BMI) value of 20.0 to 35.0 kg/m2 at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        At the time of obtaining informed consent:&#xD;
&#xD;
          -  Subject has type 2 diabetes mellitus.&#xD;
&#xD;
          -  Subject has participated or has been participating in a clinical study or a post&#xD;
             marketing study of another drug or medical equipment within 12 weeks (84 days) prior&#xD;
             to obtaining informed consent.&#xD;
&#xD;
          -  Subject has received ASP1941 (ipragliflozin) with the exception of placebo.&#xD;
&#xD;
        At screening period:&#xD;
&#xD;
          -  Subject has proliferative retinopathy (subjects with stable condition after&#xD;
             photocoagulation etc. may be enrolled in the study).&#xD;
&#xD;
          -  Subject has developed hypoglycemia unawareness (requires help of a third person) or&#xD;
             severe hypoglycemia (diabetic coma, precoma, or convulsion) within 12 weeks (84 days)&#xD;
             prior to the start of screening.&#xD;
&#xD;
          -  Subject has developed diabetic ketoacidosis within 12 weeks (84 days) prior to the&#xD;
             start of screening.&#xD;
&#xD;
          -  Subject has chronic disease(s) which require the continuous use of corticosteroids or&#xD;
             immunosuppressants (oral administration, injection, inhalation, or suppository).&#xD;
&#xD;
          -  Subject has received hypoglycemic agent(s) other than insulin within 12 weeks (83&#xD;
             days) prior to the start of screening.&#xD;
&#xD;
          -  Subject with perioperative, severe infection or serious injury.&#xD;
&#xD;
          -  Subject whose serum creatinine value exceeds the upper limit of normal range at&#xD;
             screening.&#xD;
&#xD;
          -  Subject has a urinary albumin/urinary creatinine ratio&gt;300 mg/g in urinalysis at&#xD;
             screening.&#xD;
&#xD;
          -  Subject has a history of clinically significant renal disease(s) such as renovascular&#xD;
             occlusive disease, nephrectomy, and/or renal transplant.&#xD;
&#xD;
          -  Subject has AST and ALT &gt;2 ×ULN or T-Bil &gt;1.5 × ULN at screening, or has a history of&#xD;
             serious hepatic diseases.&#xD;
&#xD;
          -  Subject presents with symptoms of dysuria, anuria, oliguria and urinary retention.&#xD;
&#xD;
          -  Subject has a history of recurrent urinary tract infections and recurrent genital&#xD;
             infections (developed 3 times or more within 24 weeks (168 days) prior to the start of&#xD;
             screening).&#xD;
&#xD;
          -  Subject has urinary tract infection or genital infection with subjective symptoms.&#xD;
&#xD;
          -  Subject has a history of angina unstable, myocardial infarction, angioplasty, and&#xD;
             serious heart disease (NYHA Class II-IV) within 24 weeks (168 days) prior to the start&#xD;
             of screening, or has complications of heart disease that, in the investigator's or&#xD;
             sub-investigator's opinion, may interfere with the evaluation of safety of ASP1941.&#xD;
&#xD;
          -  Subject has uncontrolled blood pressure (systolic blood pressure≥160 mmHg or diastolic&#xD;
             blood pressure≥100 mmHg in the supine position after a 5-minute rest at screening ).&#xD;
&#xD;
          -  Subject has serious gastrointestinal disease or a history of serious gastrointestinal&#xD;
             operation.&#xD;
&#xD;
          -  Subject has malignant tumors concomitantly (subject may be enrolled in the study if&#xD;
             the subject has a history of a malignant tumor which has not recurred without any&#xD;
             treatment within 5 years prior to the start of screening).&#xD;
&#xD;
          -  Subject has psychiatric disorder that makes the subject unsuitable for study&#xD;
             participation.&#xD;
&#xD;
          -  Subject has drug addiction or alcohol abuse.&#xD;
&#xD;
          -  Subject has a history of drug allergies.&#xD;
&#xD;
          -  Subject is unable to adhere to any of the compliance such as hospital visits and dose&#xD;
             instruction specified in this study, or does not agree with it.&#xD;
&#xD;
          -  Subject has donated 400 mL of whole blood within 90 days, 200 mL of whole blood within&#xD;
             30 days, or blood components within 14 days prior to the start of screening.&#xD;
&#xD;
          -  Subject has any condition that, in the investigator's or sub-investigator's opinion,&#xD;
             makes the subject unsuitable for study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00006</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00002</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00009</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00005</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00008</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00003</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00004</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00010</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00011</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00007</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/hcp/study.aspx?ID=307</url>
    <description>Link to results on the Astellas Clinical Study Results website</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP1941</keyword>
  <keyword>type 1 diabetes mellitus</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipragliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

